ImmunityBio, Inc. (IBRX) Stock

ImmunityBio, Inc. (IBRX) is a Healthcare stock trading at $7.34 (as of 2026-06-18), with a market capitalization of $7.88B and a trailing P/E of -8.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

ImmunityBio, Inc. is a clinical-stage biotechnology company developing therapies and vaccines aimed at cancers and infectious diseases. Its programs include immunotherapy and cell-therapy approaches such as antibody cytokine fusion proteins, synthetic immunomodulators, and immune-cell and T-cell–based treatments for solid and liquid tumors and pathogens like SARS-CoV-2 and HIV.

Valuation — source: SEC EDGAR (first-party)
Price	$7.34
Market Cap	$7.88B
P/E Ratio	-8.8
EV / EBITDA	-31.3
Price / Book	-9.06
Price / Sales	55.87
DCF Value (model)	$-5.03
DCF Upside vs Price	-168.5%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$113.29M
Net Margin	-310.2%
Return on Equity	98.3%
Debt / Equity	-0.00
Current Ratio	6.67
Revenue Growth (YoY)	668.3%
EPS Growth (YoY)	-35.6%
FCF Growth (YoY)	-22.4%

Financial Health — source: SEC EDGAR
Altman Z-Score	-6.65 (distress)
Piotroski F-Score	4/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	-8.8
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-142.2%
vs Industry	-151.3%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	BlackRock, Inc. ($202.08M)
Institutional Holders Tracked	10
Congressional Trades (recent)	1

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Richard Gerald Adcock
Employees	671
Country	US
IPO Date	2015-07-28

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.